Compare ORC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | PHAR |
|---|---|---|
| Founded | 2010 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 793.4M |
| IPO Year | 2011 | 2020 |
| Metric | ORC | PHAR |
|---|---|---|
| Price | $6.09 | $10.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 3.9M | 16.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 17.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.28 | $10.04 |
| Revenue Next Year | $5.71 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $9.62 |
| 52 Week High | $8.40 | $21.34 |
| Indicator | ORC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 41.91 |
| Support Level | N/A | $9.62 |
| Resistance Level | $7.00 | $13.51 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 1.79 | 14.89 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.